Solid Tumor: Clinical Trials

7 trials for Solid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 completed, 1 active not recruiting, 1 withdrawn. 7 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 47Recruiting 3, Completed 2, Active not recruiting 1, Withdrawn 1

Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
Bevacizumab - Solid Tumor
Phase 4RecruitingHebei Medical University Fourth Hospital752022-03-312025-12-11
Propofol vs Sevo for Paediatric Tumor Surgery
propofol, sevoflurane - Solid Tumor, Carcinoma
Phase 4RecruitingHong Kong Children's Hospital1002021-01-112022-03-16
Durvalumab Long-Term Safety and Efficacy Study
Durvalumab - Solid Tumor
Phase 4CompletedAstraZeneca1632019-09-052024-12-20
Dabrafenib and/or Trametinib Rollover Study
dabrafenib, trametinib - Melanoma, Non Small Cell Lung Cancer
Phase 4RecruitingNovartis Pharmaceuticals1002018-01-262026-11-10
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Ibrutinib - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
Phase 4Active not recruitingPharmacyclics Switzerland GmbH2972017-05-222025-10-30
Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
denosumab, pamidronate - Solid Tumor, Metastatic Bone Disease
Phase 4WithdrawnAmgen2014-11-012015-02-18
Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype
CPT-11, Raltegravir (Isentress®), Midazolam - Solid Tumor
Phase 4CompletedNational University Hospital, Singapore252010-04-012012-11-01

Narrower conditions

Carcinoma, Non-Small-Cell Lung (2)  ·  Bone Diseases (1)  ·  Carcinoma (1)  ·  Glioma (1)  ·  Graft vs Host Disease (1)  ·  Leukemia, B-Cell (1)  ·  Lung Neoplasms (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Melanoma (1)  ·  Neoplasms (1)  ·  Neoplastic Cells, Circulating (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Bronchial Neoplasms (2)  ·  Carcinoma, Bronchogenic (2)  ·  Lung Diseases (2)  ·  Neoplasms by Site (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)  ·  Thoracic Neoplasms (2)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia (1)

Interventions

Bevacizumab (1)  ·  Denosumab (1)  ·  Irinotecan (1)  ·  Midazolam (1)  ·  Pamidronate (1)  ·  Propofol (1)  ·  Raltegravir Potassium (1)  ·  Sevoflurane (1)  ·  dabrafenib (1)  ·  durvalumab (1)  ·  ibrutinib (1)  ·  trametinib (1)

Sponsors

Amgen (1)  ·  AstraZeneca (1)  ·  Hebei Medical University Fourth Hospital (1)  ·  Hong Kong Children's Hospital (1)  ·  National University Hospital, Singapore (1)  ·  Novartis Pharmaceuticals (1)  ·  Pharmacyclics Switzerland GmbH (1)

Countries

Canada (3)  ·  Czechia (3)  ·  France (3)  ·  Hungary (3)  ·  Russia (3)  ·  Spain (3)  ·  United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  China (2)  ·  Germany (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Poland (2)  ·  South Korea (2)

Top investigators

Boon Cher Goh, MRCP (1)  ·  Jared Weiss, MD (1)  ·  Kevin Wu (1)  ·  Sau Man Lee, MBBS (1)

Results publications

PMID 26808671

NIH funding

2016 (1), 2019 (1), 2023 (1)